Ladenburg Thalmann Upgrades Xenoport (XNPT) to Buy
More News related to XNPT
- XenoPort (XNPT) and Astellas Pharma Announce an Application for RLS Treatment XP13512 Filed with PMDA in Japan
- Astellas and XenoPort Announce Submission of a New Drug Application in Japan Requesting PMDA Approval of ASP8825/XP13512 for Restless Legs Syndrome
- CORRECTING and REPLACING GlaxoSmithKline and XenoPort Announce Extension of GSK1838262 (XP13512) FDA Review Date to February 9, 2010
- Glaxo (GSK) and XenoPort (XNPT) Announed that U.S. FDA Has Extended the Review Date of GSK1838262/XP13512
- GlaxoSmithKline and XenoPort Announce Extension of GSK1838262 (XP13512) FDA Review Date to February 9, 2010
More News related to Upgrades
- Cephalon (CEPH) Files Patent Infringement Lawsuit Against Teva (TEVA)
- Needham Lifts Price Target on Dyax (DYAX) to $8
- Novo Nordisk (NVO) Atophic Vaginitis Treatment Approved by U.S. FDA
- AEterna (AEZS) Announces FDA Fast Track Status for KRX-0401
- Keryx (KERX) Granted FDA Fast Track Designation for KRX-0401
Ladenburg Thalmann upgrades Xenoport (Nasdaq: XNPT) to Buy. Price target increased from $19 to $25.
To see more analyst ratings on XNPT Click Here.
XenoPort, Inc. is a biopharmaceutical company. The Company is focused on developing a portfolio of internally discovered product candidates that utilize the body’s natural nutrient transport mechanisms to improve the therapeutic benefits of existing drugs.
Related Categories
UpgradesStocks Mentioned
+0.07Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
